The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Saphnelo (anifrolumab) to treat adult patients with systemic lupus erythematosus (SLE).
The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH).
The World Health Organization (WHO) has added Regeneron Pharmaceuticals and Roche's Covid-19 antibody drug cocktail to the list of treatments for Covid-19 patients.
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a booster dose of Pfizer-BioNTech’s Covid-19 vaccine.
The US Food and Drug Administration (FDA) has approved Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab).
Health Canada has granted full approval to Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty Covid-19 vaccines for use in individuals aged 12 years and above.
Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM to treat schizophrenia has been accepted by the US Food and Drug Administration (FDA).
The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures in paediatric patients aged one month and above.
Forxiga, a SGLT2 inhibitor, is the first medicine to secure approval for the treatment of CKD in Japan.
Pfizer and its partner BioNTech are seeking approval from the US Food and Drug Administration (FDA) for their booster dose of Covid-19 vaccine, Comirnaty, for individuals aged 16 years and above.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.